Sofosbovir and daclatasvir have been used successfully since 2013 for hepatitis C virus treatment .It has been shown by different studies that sofosbovir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between HCV RNA polymerase and SARS-CoV-2 has also been established. The efficacy of sofosbuvir and daclatsvir as potential choices in treating patients with COVID-19 and their recovery can be hypothesized.
A mini-review on Sofosbuvir and Daclatasvir treatment in COVID-19